Concise Review: Cell Therapy for Critical Limb Ischemia: An Integrated Review of Preclinical and Clinical Studies

Stem Cells

Volumn 36, Issue 2, 2018, Pages 161-171

  Qadura, Mohammad ^a,b   Terenzi, Daniella C ^a,b   Verma, Subodh ^a,b   Al Omran, Mohammed ^a,b   Hess, David A ^a,b,c,d  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d WESTERN UNIVERSITY   (Canada)

Author keywords

Angiogenesis; Arteriogenesis; Atherosclerosis; Cell therapy; Critical limb ischemia; Endothelial progenitor cells; Hematopoietic progenitor cells; Multipotent mesenchymal stem cells; Peripheral artery disease; Transplantation; Vasculogenesis

Indexed keywords

ANGIOGENESIS; BLOOD VESSEL; BONE MARROW DERIVED MONONUCLEAR CELL; CELL EXPANSION; CELL FUNCTION; CELL SURVIVAL; CELL THERAPY; COMORBIDITY; CRITICAL LIMB ISCHEMIA; EXOSOME; HUMAN; MONONUCLEAR CELL; MONONUCLEAR STEM CELL; NONHUMAN; PATIENT SELECTION; PURIFICATION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; TISSUE REGENERATION; ANIMAL; BIOLOGICAL THERAPY; BONE MARROW TRANSPLANTATION; ISCHEMIA; LIMB; PATHOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROCEDURES; WOUND HEALING;

ANIMALS; BONE MARROW TRANSPLANTATION; CELL- AND TISSUE-BASED THERAPY; EXTREMITIES; HUMANS; ISCHEMIA; PERIPHERAL ARTERIAL DISEASE; WOUND HEALING;

EID: 85038417894     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.2751     Document Type: Review

References (116)

1. Fowkes FGR, Rudan D, Rudan I et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis. Lancet 2013;382:1329–1340.
2. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res 2015;116:1509–1526.
3. Cooke JP, Losordo DW. Modulating the vascular response to limb ischemia: Angiogenic and cell therapies. Circ Res 2015;116:1561–1578.
4. Norgren L, Hiatt WR, Dormandy JA et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 2007;45 Suppl S:S5–67.
5. Conte MS, Pomposelli FB, Clair DG et al. Society for vascular surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities management of asymptomatic disease and claudication. Introduction. J Vasc Surg 2015;61:1S.
6. Anderson JL, Halperin JL, Albert NM et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:1425–1443.
7. Davies MG. Critical limb ischemia: Cell and molecular therapies for limb salvage. Methodist Debakey Cardiovasc J 2012;8:20–27.
8. Raval Z, Losordo DW. Cell therapy of peripheral arterial disease: From experimental findings to clinical trials. Circ Res 2013;112:1288–1302.
9. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971;285:1182–1186.
10. Folkman J, Merler E, Abernathy C et al. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971;133:275–288.
11. Semenza GL. Vasculogenesis, angiogenesis, and arteriogenesis: Mechanisms of blood vessel formation and remodeling. J Cell Biochem 2007;102:840–847.
12. Mentzer SJ, Konerding MA. Intussusceptive angiogenesis: Expansion and remodeling of microvascular networks. Angiogenesis 2014;17:499–509.
13. Arpino JM, Nong Z, Li F et al. Four-dimensional microvascular analysis reveals that regenerative angiogenesis in ischemic muscle produces a flawed microcirculation. Circ Res 2017;120:1453–1465.
14. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964–967.
15. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest 1999;103:1231–1236.
16. Peichev M, Naiyer AJ, Pereira D et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000;95:952–958.
17. Madeddu P, Emanueli C, Pelosi E et al. Transplantation of low dose CD34+KDR+ cells promotes vascular and muscular regeneration in ischemic limbs. FASEB J 2004;18:1737–1739.
18. Ziegler BL, Valtieri M, Porada GA et al. KDR receptor: A key marker defining hematopoietic stem cells. Science 1999;285:1553–1558.
19. Yoder MC, Mead LE, Prater D et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007;109:1801–1809.
20. Aicher A, Heeschen C, Mildner-Rihm C et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003;9:1370–1376.
21. Urbich C, Heeschen C, Aicher A et al. Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 2003;108:2511–2516.
22. Urbich C, Dimmeler S. Endothelial progenitor cells: Characterization and role in vascular biology. Circ Res 2004;95:343–353.
23. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003;9:653–660.
24. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005;438:932–936.
25. Ruiz de Almodovar C, Luttun A, Carmeliet P. An SDF-1 trap for myeloid cells stimulates angiogenesis. Cell 2006;124:18–21.
26. Fung E, Helisch A. Macrophages in collateral arteriogenesis. Front Physiol 2012;3:353.
27. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315–317.
28. Maitra B, Szekely E, Gjini K et al. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 2004;33:597–604.
29. Salem HK, Thiemermann C. Mesenchymal stromal cells: Current understanding and clinical status. Stem Cells 2010;28:585–596.
30. Si Y, Zhao Y, Hao H et al. Infusion of mesenchymal stem cells ameliorates hyperglycemia in type 2 diabetic rats: Identification of a novel role in improving insulin sensitivity. Diabetes 2012;61:1616–1625.
31. Caplan AI, Correa D. The MSC: An injury drugstore. Cell Stem Cell 2011;9:11–15.
32. Hung SC, Pochampally RR, Chen SC et al. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells 2007;25:2363–2370.
33. Kinnaird T, Stabile E, Burnett MS et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004;94:678–685.
34. Teraa M, Sprengers RW, van der Graaf Y et al. Autologous bone marrow-derived cell therapy in patients with critical limb ischemia: A meta-analysis of randomized controlled clinical trials. Ann Surg 2013;258:922–929.
35. Rigato M, Monami M, Fadini GP. Autologous cell therapy for peripheral arterial disease: Systematic review and meta-analysis of randomized, nonrandomized, and noncontrolled studies. Circ Res 2017;120:1326–1340.
36. Tateishi-Yuyama E, Matsubara H, Murohara T et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial. Lancet 2002;360:427–435.
37. Matoba S, Tatsumi T, Murohara T et al. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J 2008;156:1010–1018.
38. Procházka V, Gumulec J, Jalůvka F et al. Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer. Cell Transplant 2010;19:1413–1424.
39. Benoit E, O'Donnell TF, Jr., Iafrati MD et al. The role of amputation as an outcome measure in cellular therapy for critical limb ischemia: Implications for clinical trial design. J Transl Med 2011;9:165.
40. Li M, Zhou H, Jin X et al. Autologous bone marrow mononuclear cells transplant in patients with critical leg ischemia: Preliminary clinical results. Exp Clin Transplant 2013;11:435–439.
41. Walter DH, Krankenberg H, Balzer JO et al. Intraarterial administration of bone marrow mononuclear cells in patients with critical limb ischemia: A randomized-start, placebo-controlled pilot trial (PROVASA). Circ Cardiovasc Interv 2011;4:26–37.
42. Teraa M, Sprengers RW, Schutgens RE et al. Effect of repetitive intra-arterial infusion of bone marrow mononuclear cells in patients with no-option limb ischemia: The randomized, double-blind, placebo-controlled Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-arterial Supplementation (JUVENTAS) trial. Circulation 2015;131:851–860.
43. Van Tongeren RB, Hamming JF, Fibbe WE et al. Intramuscular or combined intramuscular/intra-arterial administration of bone marrow mononuclear cells: A clinical trial in patients with advanced limb ischemia. J Cardiovasc Surg (Torino) 2008;49:51–58.
44. Huang P, Li S, Han M et al. Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 2005;28:2155–2160.
45. Huang PP, Yang XF, Li SZ et al. Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans. Thromb Haemost 2007;98:1335–1342.
46. Ozturk A, Kucukardali Y, Tangi F et al. Therapeutical potential of autologous peripheral blood mononuclear cell transplantation in patients with type 2 diabetic critical limb ischemia. J Diabetes Complicat 2012;26:29–33.
47. Losordo DW, Kibbe MR, Mendelsohn F et al. A randomized, controlled pilot study of autologous CD34+ cell therapy for critical limb ischemia. Circ Cardiovasc Interv 2012;5:821–830.
48. Perin EC, Silva G, Gahremanpour A et al. A randomized, controlled study of autologous therapy with bone marrow-derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia. Catheter Cardiovasc Interv 2011;78:1060–1067.
49. Powell RJ, Marston WA, Berceli SA et al. Cellular therapy with Ixmyelocel-T to treat critical limb ischemia: The randomized, double-blind, placebo-controlled RESTORE-CLI trial. Mol Ther 2012;20:1280–1286.
50. Szabo GV, Kovesd Z, Cserepes J et al. Peripheral blood-derived autologous stem cell therapy for the treatment of patients with late-stage peripheral artery disease-resu of the short- and long-term follow-up. Cytotherapy 2013;15:1245–1252.
51. Lu D, Chen B, Liang Z et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: A double-blind, randomized, controlled trial. Diabetes Res Clin Pract 2011;92:26–36.
52. Gupta PK, Chullikana A, Parakh R et al. A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia. J Transl Med 2013;11:143.
53. Capoccia BJ, Robson DL, Levac KD et al. Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity. Blood 2009;113:5340–5351.
54. Losordo DW, Dimmeler S. Therapeutic angiogenesis and vasculogenesis for ischemic disease: Part II: Cell-based therapies. Circulation 2004;109:2692–2697.
55. Aicher A, Rentsch M, Sasaki K et al. Nonbone marrow-derived circulating progenitor cells contribute to postnatal neovascularization following tissue ischemia. Circ Res 2007;100:581–589.
56. Schatteman GC, Awad O. In vivo and in vitro properties of CD34+ and CD14+ endothelial cell precursors. Adv Exp Med Biol 2003;522:9–16.
57. Case J, Mead LE, Bessler WK et al. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 2007;35:1109–1118.
58. Awad O, Dedkov EI, Jiao C et al. Differential healing activities of CD34+ and CD14+ endothelial cell progenitors. Arterioscler Thromb Vasc Biol 2006;26:758–764.
59. Seneviratne AK, Bell GI, Sherman SE et al. Expanded hematopoietic progenitor cells reselected for high aldehyde dehydrogenase activity demonstrate islet regenerative functions. Stem Cells 2016;34:873–887.
60. Putman DM, Liu KY, Broughton HC et al. Umbilical cord blood-derived aldehyde dehydrogenase-expressing progenitor cells promote recovery from acute ischemic injury. Stem Cells 2012;30:2248–2260.
61. Hess DA, Wirthlin L, Craft TP et al. Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood 2006;107:2162–2169.
62. Hess DA, Meyerrose TE, Wirthlin L et al. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood 2004;104:1648–1655.
63. Crisan M, Yap S, Casteilla L et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 2008;3:301–313.
64. Au P, Tam J, Fukumura D et al. Small blood vessel engineering. Methods Mol Med 2007;140:183–195.
65. Anderson JD, Johansson HJ, Graham CS et al. Comprehensive Proteomic Analysis of Mesenchymal Stem Cell Exosomes Reveals Modulation of Angiogenesis via Nuclear Factor-KappaB Signaling. Stem Cells 2016;34:601–613.
66. Sherman SE, Kuljanin M, Cooper TT etet al. High aldehyde dehydrogenase activity identifies a subset of human mesenchymal stromal cells with vascular regenerative potential. Stem Cells 2017;35:1542–1553.
67. Peeters Weem SM, Teraa M, de Borst GJ et al. Bone marrow derived cell therapy in critical limb ischemia: A Meta-analysis of Randomized Placebo Controlled Trials. Eur J Vasc Endovasc Surg 2015;50:775–783.
68. Madaric J, Klepanec A, Valachovicova M et al. Characteristics of responders to autologous bone marrow cell therapy for no-option critical limb ischemia. Stem Cell Res Ther 2016;7:116.
69. A futile cycle in cell therapy. Nat Biotech 2017;35:291–291.
70. Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med 2003;9:702–712.
71. Putman DM, Hess DA. Isolation of human umbilical cord blood aldehyde dehydrogenase-expressing progenitor cells that modulate vascular regenerative functions in vitro and in vivo. Curr Protoc Stem Cell Biol 2013;Chapter 2:Unit 2A 10.
72. Takakura N, Watanabe T, Suenobu S et al. A role for hematopoietic stem cells in promoting angiogenesis. Cell 2000;102:199–209.
73. Schatteman GC, Hanlon HD, Jiao C et al. Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. J Clin Invest 2000;106:571–578.
74. Lyden D, Hattori K, Dias S et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001;7:1194–1201.
75. Kocher AA, Schuster MD, Szabolcs MJ et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001;7:430–436.
76. Urbich C, Heeschen C, Aicher A et al. Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat Med 2005;11:206–213.
77. Jin DK, Shido K, Kopp HG et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 2006;12:557–567.
78. Hess DA Hegele RA. Linking diabetes with oxidative stress, adipokines, and impaired endothelial precursor cell function. Can J Cardiol 2012;28:629–630.
79. Fadini GP, Sartore S, Schiavon M et al. Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia-reperfusion injury in rats. Diabetologia 2006;49:3075–3084.
80. Jialal I, Devaraj S, Singh U et al. Decreased number and impaired functionality of endothelial progenitor cells in subjects with metabolic syndrome: Implications for increased cardiovascular risk. Atherosclerosis 2010;211:297–302.
81. Tepper OM, Carr J, Allen RJ, Jr et al. Decreased circulating progenitor cell number and failed mechanisms of stromal cell-derived factor-1alpha mediated bone marrow mobilization impair diabetic tissue repair. Diabetes 2010;59:1974–1983.
82. Fadini GP, Sartore S, Albiero M et al. Number and function of endothelial progenitor cells as a marker of severity for diabetic vasculopathy. Arterioscler Thromb Vasc Biol 2006;26:2140–2146.
83. Werner N, Kosiol S, Schiegl T et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005;353:999–1007.
84. Vasa M, Fichtlscherer S, Aicher A et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001;89:E1–E7.
85. Nakamura-Ishizu A, Takizawa H Suda T. The analysis, roles and regulation of quiescence in hematopoietic stem cells. Development 2014;141:4656–4666.
86. Hill JM, Zalos G, Halcox JP et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:593–600.
87. Sibal L, Aldibbiat A, Agarwal SC et al. Circulating endothelial progenitor cells, endothelial function, carotid intima-media thickness and circulating markers of endothelial dysfunction in people with type 1 diabetes without macrovascular disease or microalbuminuria. Diabetologia 2009;52:1464–1473.
88. Goldschmidt-Clermont PJ, Seo DM, Wang L et al. Inflammation, stem cells and atherosclerosis genetics. Curr Opin Mol Ther 2010;12:712–723.
89. Kizilay Mancini O, Lora M, Shum-Tim D et al. A proinflammatory secretome mediates the impaired immunopotency of human mesenchymal stromal cells in elderly patients with atherosclerosis. Stem Cells Translational Medicine 2017;6:1132–1140.
90. Weinberg I, Jaff MR. Nonatherosclerotic arterial disorders of the lower extremities. Circulation 2012;126:213–222.
91. Idei N, Soga J, Hata T et al. Autologous bone-marrow mononuclear cell implantation reduces long-term major amputation risk in patients with critical limb ischemia: A comparison of atherosclerotic peripheral arterial disease and Buerger disease. Circ Cardiovasc Interv 2011;4:15–25.
92. Perin EC, Murphy M, Cooke JP et al. Rationale and design for PACE: Patients with intermittent claudication injected with ALDH bright cells. Am Heart J 2014;168:667–673.
93. Yoder MC, Ingram DA. Endothelial progenitor cell: Ongoing controversy for defining these cells and their role in neoangiogenesis in the murine system. Curr Opin Hematol 2009;16:269–273.
94. Rosenzweig A. Cardiac cell therapy–mixed results from mixed cells. N Engl J Med 2006;355:1274–1277.
95. Higashi Y, Kimura M, Hara K et al. Autologous bone-marrow mononuclear cell implantation improves endothelium-dependent vasodilation in patients with limb ischemia. Circulation 2004;109:1215–1218.
96. Saito Y, Sasaki K, Katsuda Y et al. Effect of autologous bone-marrow cell transplantation on ischemic ulcer in patients with Buerger's disease. Circ J 2007;71:1187–1192.
97. Csaszar E, Kirouac DC, Yu M et al. Rapid expansion of human hematopoietic stem cells by automated control of inhibitory feedback signaling. Cell Stem Cell 2012;10:218–229.
98. Kirouac DC, Zandstra PW. The systematic production of cells for cell therapies. Cell Stem Cell 2008;3:369–381.
99. Chute JP, Muramoto GG, Whitesides J et al. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci USA 2006;103:11707–11712.
100. Fares I, Chagraoui J, Gareau Y et al. Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. Science 2014;345:1509–1512.
101. Gremmels H, Teraa M, Quax PH et al. Neovascularization capacity of mesenchymal stromal cells from critical limb ischemia patients is equivalent to healthy controls. Mol Ther 2014;22:1960–1970.
102. Todorova D, Simoncini S, Lacroix R et al. Extracellular vesicles in angiogenesis. Circ Res 2017;120:1658–1673.
103. Mathiyalagan P, Liang Y, Kim D et al. Angiogenic mechanisms of human CD34+ stem cell exosomes in the repair of ischemic hindlimb. Circ Res 2017;120:1466–1476.
104. Deregibus MC, Cantaluppi V, Calogero R et al. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 2007;110:2440–2448.
105. Kang T, Jones TM, Naddell C et al. Adipose-derived stem cells induce angiogenesis via microvesicle transport of miRNA-31. Stem Cells Translational Medicine 2016;5:440–450.
106. Compagna R, Amato B, Massa S et al. Cell therapy in patients with critical limb ischemia. Stem Cells Int 2015;2015:931420.
107. Furth ME, Atala A, Van Dyke ME. Smart biomaterials design for tissue engineering and regenerative medicine. Biomaterials 2007;28:5068–5073.
108. Badylak SF, Weiss DJ, Caplan A et al. Engineered whole organs and complex tissues. Lancet 2012;379:943–952.
109. Crapo PM, Gilbert TW, Badylak SF. An overview of tissue and whole organ decellularization processes. Biomaterials 2011;32:3233–3243.
110. Dahl SL, Blum JL, Niklason LE. Bioengineered vascular grafts: Can we make them off-the-shelf? Trends Cardiovasc Med 2011;21:83–89.
111. Dahl SL, Kypson AP, Lawson JH et al. Readily available tissue-engineered vascular grafts. Sci Transl Med 2011;3:68ra69.
112. Dijkman PE, Driessen-Mol A, Frese L et al. Decellularized homologous tissue-engineered heart valves as off-the-shelf alternatives to xeno- and homografts. Biomaterials 2012;33:4545–4554.
113. Yu C, Bianco J, Brown C et al. Porous decellularized adipose tissue foams for soft tissue regeneration. Biomaterials 2013;34:3290–3302.
114. Badylak SF, Valentin JE, Ravindra AK et al. Macrophage phenotype as a determinant of biologic scaffold remodeling. Tissue Engs Part A 2008;14:1835–1842.
115. Barc P, Skora J, Pupka A et al. Bone marrow cells in therapy of critical limb ischemia of lower extremities- own experience. Acta Angiologica 2006;12:155–166.
116. Chen B, Lu D-B, Liang et al. Autologous bone marrow mesenchymal stem cell transplantation for treatment of diabetic foot following amplification in vitro. Journal of Clinical Rehabilitation Tissue Engineering Research 2009;13:6227–6230.